HRP20110449T1 - Derivati piridina kao modulatori receptora s1p1/edg1 - Google Patents
Derivati piridina kao modulatori receptora s1p1/edg1 Download PDFInfo
- Publication number
- HRP20110449T1 HRP20110449T1 HR20110449T HRP20110449T HRP20110449T1 HR P20110449 T1 HRP20110449 T1 HR P20110449T1 HR 20110449 T HR20110449 T HR 20110449T HR P20110449 T HRP20110449 T HR P20110449T HR P20110449 T1 HRP20110449 T1 HR P20110449T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- methyl
- pyridine
- pyridinyl
- ethyl
- Prior art date
Links
- 101000693265 Homo sapiens Sphingosine 1-phosphate receptor 1 Proteins 0.000 title 1
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 31
- 239000001257 hydrogen Substances 0.000 claims abstract 29
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 29
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 26
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 23
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract 22
- 150000003839 salts Chemical class 0.000 claims abstract 17
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims abstract 10
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims abstract 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims abstract 4
- FBFDPDWTCGQHPO-UHFFFAOYSA-N 3,5-bis(2-ethylpyridin-4-yl)-1,2,4-oxadiazole Chemical compound C1=NC(CC)=CC(C=2N=C(ON=2)C=2C=C(CC)N=CC=2)=C1 FBFDPDWTCGQHPO-UHFFFAOYSA-N 0.000 claims abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- ICAMXPDSOYKTLR-UHFFFAOYSA-N 2-(2,6-dimethylpyridin-4-yl)-5-(2-methyl-6-pentan-3-ylpyridin-4-yl)-1,3,4-thiadiazole Chemical compound CC1=NC(C(CC)CC)=CC(C=2SC(=NN=2)C=2C=C(C)N=C(C)C=2)=C1 ICAMXPDSOYKTLR-UHFFFAOYSA-N 0.000 claims 1
- OEFPHQSZXAIHHA-UHFFFAOYSA-N 2-(2-ethyl-6-methylpyridin-4-yl)-5-(2-methyl-6-pentan-3-ylpyridin-4-yl)-1,3,4-thiadiazole Chemical compound CC1=NC(C(CC)CC)=CC(C=2SC(=NN=2)C=2C=C(CC)N=C(C)C=2)=C1 OEFPHQSZXAIHHA-UHFFFAOYSA-N 0.000 claims 1
- HTGUHIFSMITKAZ-UHFFFAOYSA-N 3,5-bis(2-ethyl-6-methylpyridin-4-yl)-1,2,4-oxadiazole Chemical compound CC1=NC(CC)=CC(C=2N=C(ON=2)C=2C=C(CC)N=C(C)C=2)=C1 HTGUHIFSMITKAZ-UHFFFAOYSA-N 0.000 claims 1
- DGHQHTVURCHARU-UHFFFAOYSA-N 3-(2,6-dimethylpyridin-4-yl)-5-(2-ethyl-6-methylpyridin-4-yl)-1,2,4-oxadiazole Chemical compound CC1=NC(CC)=CC(C=2ON=C(N=2)C=2C=C(C)N=C(C)C=2)=C1 DGHQHTVURCHARU-UHFFFAOYSA-N 0.000 claims 1
- PKFIOWUDLWFDRQ-UHFFFAOYSA-N 3-(2,6-dimethylpyridin-4-yl)-5-(2-methyl-6-pentan-3-ylpyridin-4-yl)-1,2,4-oxadiazole Chemical compound CC1=NC(C(CC)CC)=CC(C=2ON=C(N=2)C=2C=C(C)N=C(C)C=2)=C1 PKFIOWUDLWFDRQ-UHFFFAOYSA-N 0.000 claims 1
- UXEPPMPTMGSDFS-UHFFFAOYSA-N 3-(2,6-dimethylpyridin-4-yl)-5-(2-methyl-6-propylpyridin-4-yl)-1,2,4-oxadiazole Chemical compound CC1=NC(CCC)=CC(C=2ON=C(N=2)C=2C=C(C)N=C(C)C=2)=C1 UXEPPMPTMGSDFS-UHFFFAOYSA-N 0.000 claims 1
- GMNYRUZXHQVCQR-UHFFFAOYSA-N 3-(2,6-dimethylpyridin-4-yl)-5-[2-ethyl-6-(2-methylpropyl)pyridin-4-yl]-1,2,4-oxadiazole Chemical compound CC(C)CC1=NC(CC)=CC(C=2ON=C(N=2)C=2C=C(C)N=C(C)C=2)=C1 GMNYRUZXHQVCQR-UHFFFAOYSA-N 0.000 claims 1
- HWGIXLDYPAQRDP-UHFFFAOYSA-N 3-(2,6-dimethylpyridin-4-yl)-5-[2-methyl-6-(2-methylpropyl)pyridin-4-yl]-1,2,4-oxadiazole Chemical compound CC1=NC(CC(C)C)=CC(C=2ON=C(N=2)C=2C=C(C)N=C(C)C=2)=C1 HWGIXLDYPAQRDP-UHFFFAOYSA-N 0.000 claims 1
- VHIWEDUDPFELNB-UHFFFAOYSA-N 3-(2-ethyl-6-methylpyridin-4-yl)-5-(2-methoxy-6-pentan-3-ylpyridin-4-yl)-1,2,4-oxadiazole Chemical compound COC1=NC(C(CC)CC)=CC(C=2ON=C(N=2)C=2C=C(CC)N=C(C)C=2)=C1 VHIWEDUDPFELNB-UHFFFAOYSA-N 0.000 claims 1
- ALHBLSYGZQMVNI-UHFFFAOYSA-N 3-(2-ethyl-6-methylpyridin-4-yl)-5-(2-methyl-6-pentan-3-ylpyridin-4-yl)-1,2,4-oxadiazole Chemical compound CC1=NC(C(CC)CC)=CC(C=2ON=C(N=2)C=2C=C(CC)N=C(C)C=2)=C1 ALHBLSYGZQMVNI-UHFFFAOYSA-N 0.000 claims 1
- TYBVLPOAZRULRP-UHFFFAOYSA-N 3-(2-ethyl-6-methylpyridin-4-yl)-5-(2-methyl-6-propan-2-yloxypyridin-4-yl)-1,2,4-oxadiazole Chemical compound CC1=NC(CC)=CC(C=2N=C(ON=2)C=2C=C(OC(C)C)N=C(C)C=2)=C1 TYBVLPOAZRULRP-UHFFFAOYSA-N 0.000 claims 1
- XQEGXKNSMQCFPR-UHFFFAOYSA-N 3-(2-ethyl-6-methylpyridin-4-yl)-5-(2-methyl-6-propylpyridin-4-yl)-1,2,4-oxadiazole Chemical compound CC1=NC(CCC)=CC(C=2ON=C(N=2)C=2C=C(CC)N=C(C)C=2)=C1 XQEGXKNSMQCFPR-UHFFFAOYSA-N 0.000 claims 1
- NPNNHSXQVNILOA-UHFFFAOYSA-N 3-(2-ethyl-6-methylpyridin-4-yl)-5-[2-methoxy-6-(2-methylpropyl)pyridin-4-yl]-1,2,4-oxadiazole Chemical compound CC1=NC(CC)=CC(C=2N=C(ON=2)C=2C=C(OC)N=C(CC(C)C)C=2)=C1 NPNNHSXQVNILOA-UHFFFAOYSA-N 0.000 claims 1
- WVYRAQWHFQYZNX-UHFFFAOYSA-N 3-(2-ethyl-6-methylpyridin-4-yl)-5-[2-methyl-6-(2-methylpropyl)pyridin-4-yl]-1,2,4-oxadiazole Chemical compound CC1=NC(CC)=CC(C=2N=C(ON=2)C=2C=C(CC(C)C)N=C(C)C=2)=C1 WVYRAQWHFQYZNX-UHFFFAOYSA-N 0.000 claims 1
- SLBBYPWXVVSBTA-UHFFFAOYSA-N 3-methyl-5-[5-[2-methyl-6-(2-methylpropyl)pyridin-4-yl]-1,2,4-oxadiazol-3-yl]-n-propan-2-ylpyridin-2-amine Chemical compound CC1=NC(CC(C)C)=CC(C=2ON=C(N=2)C=2C=C(C)C(NC(C)C)=NC=2)=C1 SLBBYPWXVVSBTA-UHFFFAOYSA-N 0.000 claims 1
- ZANJNBAXROIEMU-UHFFFAOYSA-N 4-[3-(2-ethyl-6-methylpyridin-4-yl)-1,2,4-oxadiazol-5-yl]-6-methyl-n-propan-2-ylpyridin-2-amine Chemical compound CC1=NC(CC)=CC(C=2N=C(ON=2)C=2C=C(NC(C)C)N=C(C)C=2)=C1 ZANJNBAXROIEMU-UHFFFAOYSA-N 0.000 claims 1
- VJJGBGPLCFMQSQ-UHFFFAOYSA-N 4-[3-(2-ethyl-6-methylpyridin-4-yl)-1,2,4-oxadiazol-5-yl]-n,6-dimethylpyridin-2-amine Chemical compound CC1=NC(CC)=CC(C=2N=C(ON=2)C=2C=C(NC)N=C(C)C=2)=C1 VJJGBGPLCFMQSQ-UHFFFAOYSA-N 0.000 claims 1
- IESJZDOUFILRLJ-UHFFFAOYSA-N 5-(2,6-diethylpyridin-4-yl)-3-(2,6-dimethylpyridin-4-yl)-1,2,4-oxadiazole Chemical compound CCC1=NC(CC)=CC(C=2ON=C(N=2)C=2C=C(C)N=C(C)C=2)=C1 IESJZDOUFILRLJ-UHFFFAOYSA-N 0.000 claims 1
- NRBDXWUCRQKLGS-UHFFFAOYSA-N 5-(2,6-diethylpyridin-4-yl)-3-(2-ethyl-6-methylpyridin-4-yl)-1,2,4-oxadiazole Chemical compound CC1=NC(CC)=CC(C=2N=C(ON=2)C=2C=C(CC)N=C(CC)C=2)=C1 NRBDXWUCRQKLGS-UHFFFAOYSA-N 0.000 claims 1
- RQIFKHVRTFYXNI-UHFFFAOYSA-N 5-(2-cyclopentyl-6-methoxypyridin-4-yl)-3-(2-ethyl-6-methylpyridin-4-yl)-1,2,4-oxadiazole Chemical compound CC1=NC(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 RQIFKHVRTFYXNI-UHFFFAOYSA-N 0.000 claims 1
- GRWOKQVBOVHBMH-UHFFFAOYSA-N 5-(2-cyclopentyl-6-methylpyridin-4-yl)-3-(2,6-dimethylpyridin-4-yl)-1,2,4-oxadiazole Chemical compound CC1=NC(C)=CC(C=2N=C(ON=2)C=2C=C(N=C(C)C=2)C2CCCC2)=C1 GRWOKQVBOVHBMH-UHFFFAOYSA-N 0.000 claims 1
- FJTWFKBPXMAFHZ-UHFFFAOYSA-N 5-(2-ethyl-6-methylpyridin-4-yl)-3-[2-methyl-6-(2-methylpropyl)pyridin-4-yl]-1,2,4-oxadiazole Chemical compound CC1=NC(CC)=CC(C=2ON=C(N=2)C=2C=C(CC(C)C)N=C(C)C=2)=C1 FJTWFKBPXMAFHZ-UHFFFAOYSA-N 0.000 claims 1
- MUAZUGTWXWRBFN-UHFFFAOYSA-N 5-[2-ethyl-6-(2-methylpropyl)pyridin-4-yl]-3-(2-ethyl-6-methylpyridin-4-yl)-1,2,4-oxadiazole Chemical compound CC1=NC(CC)=CC(C=2N=C(ON=2)C=2C=C(CC(C)C)N=C(CC)C=2)=C1 MUAZUGTWXWRBFN-UHFFFAOYSA-N 0.000 claims 1
- 208000012657 Atopic disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010038910 Retinitis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- RGOCOPQXPMOWMH-UHFFFAOYSA-N n,6-dimethyl-4-[5-[2-methyl-6-(2-methylpropyl)pyridin-4-yl]-1,2,4-oxadiazol-3-yl]pyridin-2-amine Chemical compound CC1=NC(NC)=CC(C=2N=C(ON=2)C=2C=C(CC(C)C)N=C(C)C=2)=C1 RGOCOPQXPMOWMH-UHFFFAOYSA-N 0.000 claims 1
- HHNLFPMRSAXIKN-UHFFFAOYSA-N n,n-diethyl-4-[3-(2-ethyl-6-methylpyridin-4-yl)-1,2,4-oxadiazol-5-yl]-6-methylpyridin-2-amine Chemical compound CC1=NC(N(CC)CC)=CC(C=2ON=C(N=2)C=2C=C(CC)N=C(C)C=2)=C1 HHNLFPMRSAXIKN-UHFFFAOYSA-N 0.000 claims 1
- KQXRPPPNJZILCP-UHFFFAOYSA-N n-ethyl-4-[3-(2-ethyl-6-methylpyridin-4-yl)-1,2,4-oxadiazol-5-yl]-6-methylpyridin-2-amine Chemical compound CC1=NC(NCC)=CC(C=2ON=C(N=2)C=2C=C(CC)N=C(C)C=2)=C1 KQXRPPPNJZILCP-UHFFFAOYSA-N 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000011476 stem cell transplantation Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2007053293 | 2007-08-17 | ||
| PCT/IB2008/053269 WO2009024905A1 (en) | 2007-08-17 | 2008-08-14 | Pyridine derivatives as s1p1/edg1 receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110449T1 true HRP20110449T1 (hr) | 2011-07-31 |
Family
ID=40193868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110449T HRP20110449T1 (hr) | 2007-08-17 | 2011-06-16 | Derivati piridina kao modulatori receptora s1p1/edg1 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8598208B2 (ar) |
| EP (1) | EP2195311B1 (ar) |
| JP (1) | JP5451614B2 (ar) |
| KR (1) | KR101541558B1 (ar) |
| CN (1) | CN102648198B (ar) |
| AR (1) | AR067977A1 (ar) |
| AT (1) | ATE502938T1 (ar) |
| AU (1) | AU2008290233B2 (ar) |
| BR (1) | BRPI0815190A2 (ar) |
| CA (1) | CA2695509A1 (ar) |
| CY (1) | CY1111830T1 (ar) |
| DE (1) | DE602008005770D1 (ar) |
| DK (1) | DK2195311T3 (ar) |
| ES (1) | ES2361463T3 (ar) |
| HK (1) | HK1144809A1 (ar) |
| HR (1) | HRP20110449T1 (ar) |
| MA (1) | MA31703B1 (ar) |
| MX (1) | MX2010001881A (ar) |
| MY (1) | MY153975A (ar) |
| NZ (1) | NZ583957A (ar) |
| PL (1) | PL2195311T3 (ar) |
| PT (1) | PT2195311E (ar) |
| RU (1) | RU2492168C2 (ar) |
| SI (1) | SI2195311T1 (ar) |
| TW (1) | TWI422373B (ar) |
| WO (1) | WO2009024905A1 (ar) |
| ZA (1) | ZA201001873B (ar) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5253401B2 (ja) * | 2006-09-07 | 2013-07-31 | アクテリオン ファーマシューティカルズ リミテッド | 免疫調節薬としてのピリジン−４−イル誘導体 |
| PT2069335E (pt) | 2006-09-08 | 2013-03-04 | Actelion Pharmaceuticals Ltd | Derivados de piridin-3-ilo como agentes imunomoduladores |
| EP2079734A1 (en) * | 2006-10-25 | 2009-07-22 | NeuroSearch A/S | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
| EP2125797B1 (en) * | 2007-03-16 | 2014-01-15 | Actelion Pharmaceuticals Ltd. | Amino- pyridine derivatives as s1p1 /edg1 receptor agonists |
| MY183039A (en) * | 2008-03-07 | 2021-02-08 | Idorsia Pharmaceuticals Ltd | Pyridin-2-yl derivatives as immunomodulating agents |
| AU2009227629B2 (en) | 2008-03-17 | 2014-09-04 | Actelion Pharmaceuticals Ltd | Dosing regimen for a selective S1P1 receptor agonist |
| EP2427416B1 (en) * | 2009-05-04 | 2016-03-09 | Prometic Pharma Smt Limited | Substituted aromatic compounds and pharmaceutical uses thereof |
| WO2011007324A1 (en) | 2009-07-16 | 2011-01-20 | Actelion Pharmaceuticals Ltd | Pyridin-4-yl derivatives |
| AU2012208325B2 (en) | 2011-01-19 | 2016-12-22 | Idorsia Pharmaceuticals Ltd | 2-methoxy-pyridin-4-yl derivatives |
| EP2844655A1 (en) | 2012-05-02 | 2015-03-11 | Lupin Limited | Substituted pyridine compounds as crac modulators |
| JP6322630B2 (ja) | 2012-08-17 | 2018-05-09 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | （２Ｚ，５Ｚ）−５−（３−クロロ−４−（（Ｒ）−２，３−ジヒドロキシプロポキシ）ベンジリデン）−２−（プロピルイミノ）−３−（ｏ−トリル）チアゾリジン−４−オンの製造方法及び前記方法において使用される中間体 |
| BR112015023161B1 (pt) | 2013-03-15 | 2022-11-16 | Idorsia Pharmaceuticals Ltd | Derivados de piridin-4-ila |
| CN107667104B (zh) | 2015-05-20 | 2022-03-22 | 爱杜西亚药品有限公司 | (s)-3-{4-[5-(2-环戊基-6-甲氧基-吡啶-4-基)-[1,2,4]噁二唑-3-基]-2-乙基-6-甲基-苯氧基}-丙烷-1,2-二醇的结晶形式 |
| US10111841B2 (en) | 2015-06-19 | 2018-10-30 | University Of South Florida | Stabilization of alcohol intoxication-induced cardiovascular instability |
| WO2017004608A1 (en) | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Oxadiazole modulators of s1p methods of making and using |
| WO2017004609A1 (en) | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Thiadiazole modulators of s1p and methods of making and using |
| WO2017004610A1 (en) | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Tercyclic s1p3-sparing, s1p1 receptor agonists |
| EP4148053A1 (en) | 2016-03-07 | 2023-03-15 | The Global Alliance for TB Drug Development, Inc. | Antibacterial compounds and uses thereof |
| TW201808906A (zh) | 2016-03-16 | 2018-03-16 | 拜耳作物科學股份有限公司 | 作為殺蟲劑之經取代吡啶化合物 |
| US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
| US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
| US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
| US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
| WO2022053994A1 (en) * | 2020-09-11 | 2022-03-17 | Pi Industries Limited | A process for the preparation of substituted pyridine compounds and intermediates thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3647809A (en) * | 1968-04-26 | 1972-03-07 | Chinoin Gyogyszer Es Vegyeszet | Certain pyridyl-1 2 4-oxadiazole derivatives |
| AU7686891A (en) | 1990-04-05 | 1991-10-30 | American National Red Cross, The | A protein family related to immediate-early protein expressed by human endothelial cells during differentiation |
| US6423508B1 (en) | 1998-03-09 | 2002-07-23 | Smithkline Beecham Corporation | Polynucleotide sequences of human EDG-1c |
| MXPA02001764A (es) | 1999-08-19 | 2004-03-19 | Nps Pharma Inc | Compuestos heteropoliciclicos y su uso como antagonistas de receptor de glutamato metabotropico. |
| RU2319701C2 (ru) | 2001-02-21 | 2008-03-20 | Астразенека Аб | ГЕТЕРОПОЛИЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МЕТАБОТРОПНЫХ ГЛЮТАМАТНЫХ РЕЦЕПТОРОВ mGluR ГРУППЫ I |
| US7479504B2 (en) | 2002-01-18 | 2009-01-20 | Merck & Co., Inc. | Edg receptor agonists |
| AU2003202994B2 (en) | 2002-01-18 | 2007-11-22 | Merck Sharp & Dohme Corp. | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists |
| AU2003279915A1 (en) | 2002-10-15 | 2004-05-04 | Merck And Co., Inc. | Process for making azetidine-3-carboxylic acid |
| AU2004240586A1 (en) | 2003-05-15 | 2004-12-02 | Merck & Co., Inc. | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists |
| AU2004277947A1 (en) | 2003-10-01 | 2005-04-14 | Merck & Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists |
| US7605171B2 (en) * | 2003-12-17 | 2009-10-20 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
| MXPA06013912A (es) | 2004-05-29 | 2007-07-18 | 7Tm Pharma As | Ligandos del receptor de crth2 para usos medicinales. |
| AU2006224295A1 (en) | 2005-03-17 | 2006-09-21 | Pfizer, Inc. | N- (N-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain |
| JP2008539195A (ja) | 2005-04-26 | 2008-11-13 | ノイロサーチ アクティーゼルスカブ | 新規のオキサジアゾール誘導体及びそれらの医学的使用 |
| BRPI0612028A2 (pt) | 2005-06-08 | 2010-10-13 | Novartis Ag | oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p |
| US20090054491A1 (en) | 2005-06-28 | 2009-02-26 | Astrazeneca Ab | Use |
| TWI404706B (zh) * | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| CN101370805B (zh) | 2006-01-24 | 2011-04-27 | 埃科特莱茵药品有限公司 | 吡啶衍生物 |
| GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| JP5253401B2 (ja) | 2006-09-07 | 2013-07-31 | アクテリオン ファーマシューティカルズ リミテッド | 免疫調節薬としてのピリジン−４−イル誘導体 |
| PT2069335E (pt) | 2006-09-08 | 2013-03-04 | Actelion Pharmaceuticals Ltd | Derivados de piridin-3-ilo como agentes imunomoduladores |
| US8044076B2 (en) | 2006-09-21 | 2011-10-25 | Actelion Pharmaceuticals Ltd. | Phenyl derivatives and their use as immunomodulators |
| NZ577111A (en) | 2006-12-15 | 2012-05-25 | Abbott Lab | Novel oxadiazole compounds |
| EP2125797B1 (en) | 2007-03-16 | 2014-01-15 | Actelion Pharmaceuticals Ltd. | Amino- pyridine derivatives as s1p1 /edg1 receptor agonists |
| NZ585775A (en) | 2007-11-01 | 2011-12-22 | Actelion Pharmaceuticals Ltd | Novel pyrimidine derivatives |
| CA2714665A1 (en) | 2008-03-06 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Pyridine compounds |
| US20110046170A1 (en) | 2008-03-06 | 2011-02-24 | Martin Bolli | Novel pyrimidine-pyridine derivatives |
| MY183039A (en) | 2008-03-07 | 2021-02-08 | Idorsia Pharmaceuticals Ltd | Pyridin-2-yl derivatives as immunomodulating agents |
| KR20100125380A (ko) | 2008-03-07 | 2010-11-30 | 액테리온 파마슈티칼 리미티드 | 신규한 아미노메틸 벤젠 유도체 |
| EP2913326B1 (en) | 2008-05-14 | 2020-07-15 | The Scripps Research Institute | Novel modulators of sphingosine phosphate receptors |
| WO2011007324A1 (en) | 2009-07-16 | 2011-01-20 | Actelion Pharmaceuticals Ltd | Pyridin-4-yl derivatives |
-
2008
- 2008-08-14 AU AU2008290233A patent/AU2008290233B2/en not_active Ceased
- 2008-08-14 NZ NZ583957A patent/NZ583957A/en not_active IP Right Cessation
- 2008-08-14 US US12/673,918 patent/US8598208B2/en not_active Expired - Fee Related
- 2008-08-14 SI SI200830269T patent/SI2195311T1/sl unknown
- 2008-08-14 ES ES08789611T patent/ES2361463T3/es active Active
- 2008-08-14 WO PCT/IB2008/053269 patent/WO2009024905A1/en active Application Filing
- 2008-08-14 DE DE602008005770T patent/DE602008005770D1/de active Active
- 2008-08-14 CA CA2695509A patent/CA2695509A1/en not_active Abandoned
- 2008-08-14 EP EP08789611A patent/EP2195311B1/en not_active Not-in-force
- 2008-08-14 PT PT08789611T patent/PT2195311E/pt unknown
- 2008-08-14 PL PL08789611T patent/PL2195311T3/pl unknown
- 2008-08-14 DK DK08789611.4T patent/DK2195311T3/da active
- 2008-08-14 CN CN200880103070.2A patent/CN102648198B/zh not_active Expired - Fee Related
- 2008-08-14 MX MX2010001881A patent/MX2010001881A/es active IP Right Grant
- 2008-08-14 KR KR1020107005759A patent/KR101541558B1/ko not_active IP Right Cessation
- 2008-08-14 AT AT08789611T patent/ATE502938T1/de active
- 2008-08-14 BR BRPI0815190 patent/BRPI0815190A2/pt not_active IP Right Cessation
- 2008-08-14 RU RU2010109542/04A patent/RU2492168C2/ru not_active IP Right Cessation
- 2008-08-14 JP JP2010520670A patent/JP5451614B2/ja not_active Expired - Fee Related
- 2008-08-14 MY MYPI2010000684A patent/MY153975A/en unknown
- 2008-08-15 TW TW097131346A patent/TWI422373B/zh not_active IP Right Cessation
- 2008-08-19 AR ARP080103611A patent/AR067977A1/es not_active Application Discontinuation
-
2010
- 2010-03-12 MA MA32693A patent/MA31703B1/ar unknown
- 2010-03-16 ZA ZA2010/01873A patent/ZA201001873B/en unknown
- 2010-12-03 HK HK10111281.3A patent/HK1144809A1/xx not_active IP Right Cessation
-
2011
- 2011-05-30 CY CY20111100521T patent/CY1111830T1/el unknown
- 2011-06-16 HR HR20110449T patent/HRP20110449T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110449T1 (hr) | Derivati piridina kao modulatori receptora s1p1/edg1 | |
| TWI671298B (zh) | 經取代之多環性吡啶酮衍生物及其前體藥物 | |
| JP2013539789A5 (ar) | ||
| US9725444B2 (en) | Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases | |
| CA3047336A1 (en) | Chemical compounds as inhibitors of interleukin-1 activity | |
| CA3102972A1 (en) | Hepatitis b capsid assembly modulators | |
| ES2606043T3 (es) | Derivados de biarilo como moduladores de nAChR | |
| JP2008530099A5 (ar) | ||
| CN106536480A (zh) | 吡咯烷‑2,5‑二酮衍生物、药物组合物及用作ido1抑制剂的方法 | |
| CN101087755A (zh) | 取代的芳基酰基硫脲及其相关化合物；病毒复制抑制剂 | |
| EP2074115A1 (en) | N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors | |
| KR20060072142A (ko) | Ｃｒｆ 길항제 및 이환식 복소환 화합물 | |
| AU2003248592A1 (en) | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | |
| AU8861298A (en) | 1,2,4-triazolo{4,3-b}pyrido{3,2-d}pyridazine derivatives and pharmaceutical compositions containing them | |
| JP2008506762A (ja) | 抗ウイルス剤としての、イミダゾール及びチアゾール誘導体 | |
| HU904785D0 (en) | Process for the production of medicaments | |
| ES2713403T3 (es) | Derivados de pirazolo-piridina como inhibidores de quinasa | |
| RU2010106975A (ru) | Бициклические амиды для усиления глутаматергических синаптических ответов | |
| NO20003773L (no) | Syklobutenderivater, deres fremstilling og deres terapeutiske anvendelser | |
| RU2007109601A (ru) | Антагонисты vla-4 | |
| TW201102396A (en) | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase | |
| CN113330005A (zh) | 用magl抑制剂治疗疾病的方法 | |
| MXPA02007460A (es) | Nuevos moduladores positivos alostericos del receptor de ampa (paarm) procedimientos para su preparacion y su uso como medicamentos. | |
| JP6545908B2 (ja) | 三環式化合物、及び癌治療におけるそれらの使用 | |
| KR101850142B1 (ko) | 1-(3-아미노프로필) 치환 고리형 아민계 화합물, 이의 제조방법, 약물 조성물 및 용도 |